Sera Secures $19.3 million Financing; Appoints Greg C. Critchfield, MD as Chief Executive Officer

Salt Lake City, UT – November 15, 2011 – Sera Prognostics, Inc., a women’s health company developing diagnostic tests for early prediction of preterm birth and other pregnancy complications, today announced the closing of a $19.3 million Series A financing led by venture capital firms InterWest Partners, Domain Associates and Catalyst Health Ventures. Also participating in the round are the company’s founder, UpStart Life Sciences Capital, and new investor Osage University Partners.  In addition, the company announced the appointment of Gregory C. Critchfield, M.D., former president of Myriad Genetic Laboratories, Inc. and current Chairman of Sera’s Board of Directors, to Chief Executive Officer.  Doug Fisher, M.D. of InterWest Partners, Kim P. Kamdar, Ph.D. of Domain Associates and Joshua Phillips of Catalyst Health Ventures will also be joining Sera’s Board.

Sera will use the proceeds of this financing to complete the company’s multi-center Proteomic Assessment of Preterm Risk (PAPR) clinical trial of its preterm birth diagnostic and commercially launch the test with the goal of demonstrating clinical benefit and economic savings under real-world conditions.

Full press release